PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Endocrinology and Metabolism10.3803/enm.2020.777202136170-80Effect of Teneligliptin versus Sulfonylurea on Major Adverse Cardiovascular Outcomes in People with Type 2 Diabetes Mellitus: A Real-World Study in KoreaDa Hea Seo, Kyoung Hwa Ha, So Hun Kim, Dae Jung Kimhttp://e-enm.org/upload/pdf/enm-2020-777.pdf, http://e-enm.org/journal/view.php?doi=10.3803/EnM.2020.777, http://e-enm.org/upload/pdf/enm-2020-777.pdf
Primary Care Diabetes10.1016/j.pcd.2020.04.0092020146633-638Real-world evaluation of adverse pregnancy outcomes in women with gestational diabetes mellitus in the German health care systemP Reinders, Y Zoellner, U Schneiderhttps://api.elsevier.com/content/article/PII:S1751991820302692?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1751991820302692?httpAccept=text/plain
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy10.2147/dmso.s1217702016Volume 9347-353Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)Sujoy Ghosh, Shailesh Trivedi, Debmalya Sanyal, K Modi, Sandeep Kharbhttps://www.dovepress.com/getfile.php?fileID=33445, https://www.dovepress.com/getfile.php?fileID=33445
Journal of Diabetes Mellitus10.4236/jdm.2016.6201220160602113-131Teneligliptin: Heralding Change in Type 2 DiabetesManish Maladkar, Srividya Sankar, Kushal Kamathttp://www.scirp.org/journal/doi.aspx?DOI=10.4236/jdm.2016.62012, http://file.scirp.org/xml/65290.xml, http://www.scirp.org/journal/doi.aspx?DOI=10.4236/jdm.2016.62012
10.21203/rs.3.rs-16511/v12020Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysisChun-xing Li, Shuo Liang, Lingyan Gao, Hua Liuhttps://www.researchsquare.com/article/rs-16511/v1, https://www.researchsquare.com/article/rs-16511/v1.html
Endocrine Practice10.1016/s1530-891x(20)44953-520162254Abstract #245: Cardiovascular Risks Difference Between Men and Women with Type 2 Diabetes Exposed to Sulfonylurea in Real-World Clinical Practice in CanadaPendar Farahani, Shahriar Khanhttps://api.elsevier.com/content/article/PII:S1530891X20449535?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1530891X20449535?httpAccept=text/plain
Metabolism10.1016/s0026-0495(98)90023-31998476637-643Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetesA. Panahloo, V. Mohamed-Ali, C. Andrés, A.E. Denver, J.S. Yudkinhttps://api.elsevier.com/content/article/PII:S0026049598900233?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0026049598900233?httpAccept=text/plain
Diabetes Therapy10.1007/s13300-020-00880-4202011102257-2268Teneligliptin Real-World Effectiveness Assessment in Patients with Type 2 Diabetes Mellitus in India: A Retrospective Analysis (TREAT-INDIA 2)Sujoy Ghosh, Mangesh Tiwaskar, Rajiv Chawla, Shalini Jaggi, Arthur Asirvatham, Vijay Panikarhttp://link.springer.com/content/pdf/10.1007/s13300-020-00880-4.pdf, http://link.springer.com/article/10.1007/s13300-020-00880-4/fulltext.html, http://link.springer.com/content/pdf/10.1007/s13300-020-00880-4.pdf
Diabetes mellitus10.14341/dm103742020225467-472Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agentsStefan D. Ankerhttps://dia-endojournals.ru/dia/article/viewFile/10374/pdf_1, https://dia-endojournals.ru/dia/article/viewFile/10374/pdf_1
Diabetes mellitus10.14341/2072-0351-62342011143111-112Pharmacoeconomic aspects of the use of sulfonylurea drugs in type 2 diabetes mellitusAlla Vsevolodovna Rudakovahttps://dia-endojournals.ru/dia/article/viewFile/6234/3993, https://dia-endojournals.ru/dia/article/viewFile/6234/3993